Exhibit 99.1


BrainStorm Shareholders Extend Lock-Up Agreement

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--March 29, 2006--

BrainStorm Cell Therapeutics (OTCBB: BCLI.OB), the developer of NurOwn(TM) bone
marrow derived stem cell therapeutic products for the treatment of
neurodegenerative diseases, announced today that the company has received signed
agreements from certain of the company's shareholders, representing 7,810,000
shares of the company's issued and outstanding shares, to extend a lock-up
agreement with respect to their shares, until Dec. 31, 2006. According to the
new agreement, 85 percent of the shares will be restricted from sale or other
transfer until December 31, 2006 with the remainder free of the new
restrictions.

The shares were previously subject to a lock-up agreement restricting 85 percent
of the shares from sale or other transfer until July 8, 2006. All restrictions
will automatically terminate upon the effectiveness of any registration
statement filed by the Company for the benefit of Ramot at Tel Aviv University
Ltd.

"We are pleased with these agreements which reflect our shareholders' long-term
perspective and confidence in the company," said Yoram Drucker, Chief Operations
Officer and Principal Executive of BrainStorm.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like
stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow
derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM)
patent pending technology is based on discoveries made by the team of prominent
neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and
expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research
Center of Tel-Aviv University, enabling the differentiation of bone marrow
derived stem cells into functional neurons and astrocytes, as demonstrated in
animal models. The company holds rights to develop and commercialize the
technology through an exclusive, worldwide licensing agreement with Ramot at Tel
Aviv University Ltd., the technology transfer company of Tel Aviv University.
The company's initial focus is on developing treatments for Parkinson's Disease.

About Stem Cell Therapy

Stem cells are non-specialized cells with a remarkable potential for both
self-renewal and differentiation into cell types with a specialized function,
such as muscle, blood or brain cells. Stem cells may be sourced from fetal or
embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of
embryonic stem cells, has become the center of significant ethical and moral
debate. In contrast, use of adult stem cells does not face the same moral or
legal controversy. Stem cell therapy aims to "cure" disease by replacing the
'diseased' cells with 'healthy' cells derived from stem cells. This approach has
the potential to revolutionize medicine and, if successful, the implied
commercial opportunities are great. Currently, both embryonic stem cells (ESC)
and adult stem cells (ASC) are being explored as the potential basis for
multiple cell therapy products.



Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements. The
potential risks and uncertainties include, among others, risks associated with
BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses
and expectation to incur losses for the foreseeable future; limited cash
resources and its need to raise additional capital to execute on its business
plan and continue operations; transition issues related to the departure of its
CEO; dependence on its license to Ramot's technology and ability to meet its
funding and payment obligations included in such license agreement; ability,
together with its licensor, to adequately protect the NurOwn(TM) technology;
dependence on key executives and on its scientific consultants; ability to
identify, negotiate and successfully implement strategic partnering
relationships; ability to complete clinical trials successfully and to obtain
required regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining regulatory approval
for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public
trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never
develop into an active market; and other factors detailed in BrainStorm Cell
Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form
10-QSB, current reports on Form 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to the
Company. The Company does not undertake any obligation to update forward-looking
statements made by us.


Contacts


BrainStorm Cell Therapeutics
Mike Ben-Ari +972 3 751 0090
mbaifa@netvision.net.il